Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 214,596 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 214,596 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $163.51, for a total transaction of $35,088,591.96. Following the transaction, the director owned 3,065,452 shares of the company’s stock, valued at approximately $501,232,056.52. The trade was a 6.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Illumina Stock Performance

ILMN traded up $1.44 during trading on Monday, hitting $164.40. 2,190,450 shares of the company traded hands, compared to its average volume of 1,870,323. The firm has a market cap of $24.87 billion, a P/E ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50. The stock’s fifty day moving average is $133.73 and its 200 day moving average is $132.09. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a one year low of $78.79 and a one year high of $165.97.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays increased their price target on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. UBS Group restated a “neutral” rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. JPMorgan Chase & Co. increased their price target on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $138.38.

Hedge Funds Weigh In On Illumina

Large investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its stake in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after acquiring an additional 79 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the period. Meeder Advisory Services Inc. increased its holdings in Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank increased its holdings in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the period. Finally, Assetmark Inc. increased its holdings in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.